Lotus Eye Hospital and Institute Limited
LOTUSEYE · NSE · Healthcare
StocksWizard rates Lotus Eye Hospital and Institute Limited a Sell, scoring 43/100 on our blended model. At ₹127.69 it trades above our blended DCF and relative-multiples fair value of ₹63.85, implying roughly 50% downside to that estimate — we read the stock as overvalued by 50%. Financial health scores 50/100 (grade C). It clears 4 of 10 investability checks, with durability 23, valuation 32 and momentum 84 on our 0–100 scales.
These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹51.08. Low-confidence estimate — limited data.
Investability checklist
- ✕ROE above 15%0.1%
- ✓Low debt (D/E < 0.5)0.26x
- ✕Positive free cash flow
- ✓Revenue growth > 10%18%
- –Earnings growing
- ✕Net margin ≥ 10%0.1%
- ✕Current ratio > 1.51.22
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- –Altman Z in safe zone
- –Piotroski ≥ 7
1-year price
EOD · 2026-06-19Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
Weaknesses
- •Low return on equity (0.1%).
Opportunities
- •Revenue growing (18% YoY).
Threats
- •Trades ~50% above our estimated fair value.
About Lotus Eye Hospital and Institute Limited
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediat
More in Healthcare
All stocksOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.